151 related articles for article (PubMed ID: 25489817)
1. Developers seek to finetune toxicity of T-cell therapies.
Morrison C
Nat Biotechnol; 2014 Dec; 32(12):1171-2. PubMed ID: 25489817
[No Abstract] [Full Text] [Related]
2. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.
Magnani CF; Mezzanotte C; Cappuzzello C; Bardini M; Tettamanti S; Fazio G; Cooper LJN; Dastoli G; Cazzaniga G; Biondi A; Biagi E
Hum Gene Ther; 2018 May; 29(5):602-613. PubMed ID: 29641322
[TBL] [Abstract][Full Text] [Related]
3. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
4. CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.
Quintás-Cardama A
Leuk Lymphoma; 2019 May; 60(5):1346-1348. PubMed ID: 30646790
[No Abstract] [Full Text] [Related]
5. Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
Geyer MB; Manjunath SH; Evans AG; Park JH; Davila ML; Cutler CS; Wang X; Wang Y; Senechal B; Rivière I; Sadelain M; Liesveld JL; Brentjens RJ
Leuk Lymphoma; 2018 Jul; 59(7):1717-1721. PubMed ID: 29043880
[No Abstract] [Full Text] [Related]
6. Using CD19 chimeric antigen receptor-T cell therapy in a 4-month-old patient with infantile acute lymphoblastic leukemia.
Shyr DC; Homsombath AA; Chan PP; Boyer MW; Harris AC
Pediatr Blood Cancer; 2020 Apr; 67(4):e28155. PubMed ID: 31925900
[No Abstract] [Full Text] [Related]
7. Chimeric antigen receptor T-cell immunotherapy tackles blood cancers.
Brower V
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25838441
[No Abstract] [Full Text] [Related]
8. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA
Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559
[TBL] [Abstract][Full Text] [Related]
9. CAR therapy: the CD19 paradigm.
Sadelain M
J Clin Invest; 2015 Sep; 125(9):3392-400. PubMed ID: 26325036
[TBL] [Abstract][Full Text] [Related]
10. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.
Perica K; Flynn J; Curran KJ; Rivere I; Wang X; Senechal B; Halton E; Diamonte C; Pineda J; Bernal Y; Gonen M; Sadelain M; Brentjens RJ; Park JH
Leukemia; 2021 Nov; 35(11):3268-3271. PubMed ID: 33686196
[No Abstract] [Full Text] [Related]
11. CAR T cells: The future is already present.
Sánchez-Escamilla M; Yáñez San Segundo L; Urbano-Ispizua Á; Perales MÁ
Med Clin (Barc); 2019 Apr; 152(7):281-286. PubMed ID: 30392694
[No Abstract] [Full Text] [Related]
12. Factors associated with the clinical outcome of patients with relapsed/refractory CD19
Ortiz-Maldonado V; Rives S; Español-Rego M; Alonso-Saladrigues A; Montoro M; Magnano L; Giné E; Pascal M; Díaz-Beyá M; Castella M; Català A; Faura A; Rodríguez-Lobato LG; Oliver-Caldes A; Martínez-Roca A; Rovira M; González-Navarro EA; Ortega JR; Cid J; Lozano M; Garcia-Rey E; Fernández S; Castro P; Jordan I; Villamor N; Aymerich M; Torrebadell M; Deyà À; Fernández de Larrea C; Benitez-Ribas D; Trias E; Varea S; Calvo G; Esteve J; Urbano-Ispizua A; Juan M; Delgado J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907029
[No Abstract] [Full Text] [Related]
13. Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice.
Dushenkov A; Jungsuwadee P
J Oncol Pharm Pract; 2019 Jul; 25(5):1217-1225. PubMed ID: 30890066
[TBL] [Abstract][Full Text] [Related]
14. Genetically modified T cells target lymphoma.
Nogrady B
Nature; 2018 Nov; 563(7731):S42-S43. PubMed ID: 30429568
[No Abstract] [Full Text] [Related]
15. Chimeric antigen receptor T-cell therapy for ALL.
Maude SL; Shpall EJ; Grupp SA
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):559-64. PubMed ID: 25696911
[TBL] [Abstract][Full Text] [Related]
16. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.
Lorentzen CL; Straten PT
Scand J Immunol; 2015 Oct; 82(4):307-19. PubMed ID: 26099639
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy: CAR-modified T cells targeting CD19-curing the incurable.
Hutchinson L
Nat Rev Clin Oncol; 2014 Dec; 11(12):683. PubMed ID: 25348787
[No Abstract] [Full Text] [Related]
18. Marshaling the immune system to eliminate minimal residual disease in B-ALL.
Hede K
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214564
[No Abstract] [Full Text] [Related]
19. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.
Singh H; Moyes JS; Huls MH; Cooper LJ
Cancer Gene Ther; 2015 Mar; 22(2):95-100. PubMed ID: 25591810
[TBL] [Abstract][Full Text] [Related]
20. Pediatric Acute Lymphoblastic Leukemia.
Rheingold SR
Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469898
[No Abstract] [Full Text] [Related]
[Next] [New Search]